🎙️Many thanks to Matthew Liteplo for hosting Lior Shaltiel on the OTCQB Podcast for entrepreneurs and innovators! We discussed exosomes as the ultimate drug‑delivery system and NurExone’s drive to restore lost function for patients with CNS injuries.

In person. On the radio. On TV. 🎙️📺🧠 Lior Shaltiel, PhD, brings our mission to life with clarity and passion.|.🎧Listen to Lior and Rami Shani (Hebrew only) - Thanks!

🐾 ExoPTEN Study Reveals Significant Gains in Walking Recovery in Spinal Cord Injury Animal Model. These findings provide additional support for ExoPTEN’s potential as a transformative therapy in a market with few effective options and high unmet needs.

In a new preclinical study, medium and high doses of ExoPTEN improved movement quality in up to 100% of animals after spinal cord compression surgery, a model simulating spinal cord injury!.

Florida 🌴 is emerging as a leader in regenerative medicine, with new laws supporting exosome use in wellness. A timely setting for the 2nd Global Cell & Gene Therapy Summit, where Lior Shaltiel, PhD presented — a big moment for NurExone. #CGTSummit #Exosomes #Biotech #Florida

We've been accepted into the Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA HealthTech Hub Accelerator . ✔️ Strengthening commercialization strategies.✔️ Advancing our regenerative medicine strategy in the U.S. Read more:

ICYMI: NurExone Biologic Q1 2025 Investor Recap.NurExone is making important strides in the development of its exosome-based therapy for traumatic spinal cord injurywhile laying the groundwork for broader CNS applications!

📢 Join our presentation at the Investor Summit Group online meeting on June 10, 2025 at 2:00 PM EDT 🗓️. 💻 To request free registration for this exclusive investor event focused on small and microcap stocks, go to: . See you at the Summit!!.

🔥Exosomes are definitely the next Big Thing! We are harnessing their potential to address unmet medical challenges (acute spine cord injuries, optic nerve injuries and more)!. Thanks to Channel 10 and Danny Roup for hosting us on "The Next Big Thing"!.

🏃Check out our Q1 - 2025 Results!. ✅ Included in the 2025 TSX Venture 50™ .✅ Launched U.S. subsidiary, Exo-Top Inc. ✅ C$2.3M+ raised .✅ Advancing ExoPTEN to 2026 human trials.✅ New preclinical data shared at key conferences. Read more:

Honored to have the opportunity to present NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) at Biomed Israel 2025 this week! I look forward to connecting with fellow innovators in the session: ."Rewiring the Brain: Breakthroughs in Neurotech & Neuromodulation"

📢 Preclinical data showing restored optic nerve function in a model of irreversible damage was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City. ➡️ Read more:

NurExone Biologic is proud to be attending the International Society for Cell & Gene Therapy Annual Meeting from May 7–10, 2025 in New Orleans. We invite you to connect with our team and discover our groundbreaking ExoTherapy platform!

Thanks to Danny Lieberman for hosting Lior Shaltiel, PhD for a fascinating discussion about life, exosomes, regeneration of nerves and more on the Life Sciences Today podcast.

"For me, the question of where to develop our groundbreaking nerve regeneration technology was never really a dilemma. Our innovation was born in Israel, emerging from 2 elite universities". Dr. Lior Shaltiel, CEO of NurExone.

Increasing engagement with the European investment and healthcare communities this May!. 1️⃣ INVEST 2025 – Stuttgart (May 9-10). 2️⃣ Healthtech Roadshow – Zurich (May 5-8). 3️⃣ BioProcess International Europe – Hamburg (May 12-15).

ICYMI - Successfully closed a C$2.3M raise that will help:. 🟦 Advance our clinical development .🟧 Drive U.S. expansion.🟨 Support our uplisting strategy. Next steps: U.S. growth and clinical impact. #RealMomentum #ExoPTEN #Exosomes

🚨 Exciting News from Vienna!. NurExone Biologic is proud to be attending the #ISEV2025 Meeting from April 24–27, 2025 in Vienna, Austria. Let’s discuss how we’re transforming possibilities in neural repair and beyond. See you there! 🌍💡

Preclinical study assessing two ExoPTEN dosing regimens demonstrated strong potential for spinal cord injury recovery—advancing towards IND submission and first-in-human trials! .